SOOO "Nativita" will produce innovative forms of insulin in cooperation with a Russian partner
SOOO "Nativita" and the Russian company "Geropharm" today signed an agreement on scientific and production cooperation and technology transfer for the production of innovative forms of insulins at the facilities of the Belarusian manufacturer in the town of Beshenkovichi (Vitebsk region), the company informed a correspondent.
The official ceremony took place at the "Geropharm" production site in Pushkin (Saint Petersburg). According to the document, the cooperation between the two companies will cover the production of genetically engineered human insulins and insulin analogs. SOOO "Nativita" will become the first non-state local manufacturer of cartridge forms in Belarus, which will make it possible to optimize the expenditure of budget funds when purchasing insulins from foreign manufacturers. The implementation of the project will improve diabetes mellitus therapy and meet patients' needs for modern insulin formulations, specialists noted. "We are pleased that "Geropharm", a company with strong expertise and its own technologies in this field, has become "Nativita's" partner. The start of insulin production using the Russian partner's technology and their launch on the Belarusian market will be the first stage of cooperation. In the future, it is planned to expand the portfolio of drugs for the treatment of diabetes mellitus, which will increase the accessibility of modern therapy for Belarusian patients," said Vladimir Sychev, Executive Director of "Nativita".
"Geropharm" is the only Russian manufacturer of genetically engineered human insulin on a full-cycle basis (from substance synthesis to finished dosage form). The enterprise was founded in 2001 and has two production sites in Moscow and Saint Petersburg. The volume of investments in technological innovations and R&D in 2013-2017 exceeded 6 billion Russian rubles.
SOOO "Nativita" is an international scientific and production pharmaceutical company for the development and production of innovative drugs for the treatment of oncological, autoimmune, and other serious diseases. The company has a scientific and production
a complex that includes microbiological and chemical laboratories, a drug manufacturing plant, departments for pharmaceutical development and drug registration within the department of production and technology development, as well as medical and scientific departments. The total volume of the company's product sales in 2018 amounted to $17 million, and in 2019 it is planned to increase it to $28 million, mastering the production of at least seven new drugs.